Tag: Bionexus Status Company

  • Review of Tax Incentives for Bionexus Status Company

    Review of Tax Incentives for Bionexus Status Company

    Updated on 15 July 2023- Dialogue between MOF, LHDNM, and CTIM [21/6/2023]

    To Download Revised Budget 2023 Speech and some other related publications – https://www.ccs-co.com/post/budget-2023-malaysia-madani

    Current Position

    “Bio Nexus Status Company” means a company incorporated under the Companies Act 2016 [Act 777] engaged in the life sciences business.

    Tax incentives for BioNexus status companies are given as follows:

    1. a company undertaking biotechnology activity and approved with BioNexus status:
      1. Income Tax Exemption of 70% on statutory income commencing from the first statutory income for a period of 10 or 5 years, subject to new or existing business (expansion project);
      2. concessionary tax rate of 20% on income from qualifying activities for 10 years upon the expiry of the tax exemption period;
      3. Double Tax Deduction on research & development expenditure;
      4. Industrial Building Allowance on building for biotechnology research activities; and
      5. Import Duty Exemption on raw materials / components and machinery / equipment.
    2. a company that undertakes investment in a BioNexus status subsidiary company engaging in a new project is given a tax deduction equivalent to the amount of investment made in the basis year the investment is made.

    The tax incentive is for applications received by the Malaysian Bioeconomy Development Corporation from 1 January 2021 until 31 December 2022.

    Proposal

    To encourage more industry players, it is proposed tax incentives be reviewed as follows:

    • income tax exemption on statutory income be increased from 70% to 100%; and
    • the application period for tax incentives is extended for 2 years.

    Effective Date

    For applications received by the Malaysian Bioeconomy Development Corporation from 1 January 2023 until 31 December 2024.

    Updated on 15 July 2023- Dialogue between MOF, LHDNM, and CTIM [21/6/2023]

    BioNexus status companies also get an income tax exemption which is equivalent to the allowance based on 100% of qualifying capital expenditure (“QCE”), i.e. Investment Tax Allowance (“ITA”).

    CTIM sought to confirm that the proposed two years application period extension applies to all tax incentives for BioNexus status companies, including the ITA and is not just restricted to the items listed in Appendix 19.

    MOF’s Feedback:

    Extending the 2-year application period applies to all tax incentives for BioNexus status companies, including the Investment Tax Allowance.

    Disclaimer:

    The articles, templates, and other materials on our website are provided only for your reference.

    While we strive to ensure that the information presented is current and accurate, we cannot guarantee the completeness, reliability, suitability, or availability of the website or its content, including any related graphics. Consequently, any reliance on this information is entirely at your own risk.

    If you intend to use the content of our videos and publications as a reference, we recommend that you take the following steps:

    1. Verify that the information provided is current, accurate, and complete.
    2. Seek additional professional opinions, as the scope and extent of each issue, may be unique.

    免责声明:

    我们网站上的文章、模板和其他材料只供参考。

    虽然我们努力确保所提供的信息是最新和准确的,但我们不能保证网站或其内容,包括任何相关图形的完整性、可靠性、适用性或可用性。因此,您需要承担使用这些信息所带来的风险。

    如果你打算使用我们的视频和出版物的内容作为参考,我们建议你采取以下步骤:

    1. 核实所提供的信息是最新的、准确的和完整的。
    2. 寻求额外的专业意见,因为每个问题的范围和程度,可能是独特的。

    Keep in touch with us so that you can receive timely updates

    请与我们保持联系,以获得即时更新。

    1. Website ✍️ https://www.ccs-co.com/ 2. Telegram ✍️ http://bit.ly/YourAuditor 3. Facebook ✍

    4. Blog ✍ https://lnkd.in/e-Pu8_G 5. Google ✍ https://lnkd.in/ehZE6mxy

    6. LinkedIn ✍ https://www.linkedin.com/company/74734209/admin/

    17
  • Tax Incentive for Investment  in a Bionexus Status Company

    Tax Incentive for Investment in a Bionexus Status Company

    Principal Rules – Tax Incentive

    According to the Income Tax (Deduction for Investment in a BioNexus Status Company) Rules 2016 [P.U.(A) 306/2016]:

    • a qualifying person is permitted a deduction of an amount equivalent to the actual value of investment made by the qualifying person in a BioNexus Status Company
    • for the investment period between January 1, 2016, and December 31, 2020. 

    Amendment Rules

    On 22 June 2022, the Minister, in the exercise of the powers conferred by paragraph 154(1)(b) of the Income Tax Act 1967 [Act 53], gazetted the Income Tax (Deduction for Investment in a Bionexus Status Company) (Amendment) Rules 2022 [P.U (A) 212/2022].

    The Amendment Rules, deemed to have come into operation on January 1, 2021, have extended the eligibility period for the incentive to include qualifying investments made from January 1, 2021, all the way through December 31, 2022.

    A Friendly Reminder

    It is important to keep in mind that in order to be eligible for this tax incentive, the conditions that are outlined in the Principal Rules must be satisfied.

    Conditions for Deductions

    The investment made by the qualifying person in a BioNexus status company must be approved by the Minister of Finance.

    The application must be submitted on or after the 1st of January 2021 and not later than the 31st of December 2022 through the Malaysian Bioeconomy Corporation Sdn Bhd.

    Malaysia Bioeconomy Development Corporation Sdn. Bhd

    means a company incorporated under the Companies Act 2016/1965 whose function is for the purpose of developing the biotechnology industry in Malaysia.

    Qualifying Person means—

    1. a company incorporated under the Companies which is not related to another company which has been given a similar tax deduction for investment into a BioNexus status company [Rule 4(1)(b)]; or
    2. an individual who is a Malaysian citizen, resident and has a business income source, and who is not a family member/relative of a person who owns any of the paid-up capital of the BioNexus status company [Rule 4(1)(c)].

    BioNexus Status Company means—

    A company incorporated under the Companies Act which is engaged in a business of life sciences such as:

    • biology, medicine;
    • anthropology, ecology; or
    • any other branches of science

    which deal with living organisms and their organisation, life processes and relationships to each other and their environment.

    Qualifying Investment

    The investment must be for the purpose of financing activities at the initiation of commercialisation stage of a new business approved by the Minister.

    • “new business” means the first biotechnology business undertaken by a BioNexus status company;
    • initiation of commercialization stage” means the stage of research, assessment and development of an initial concept or prototype before the technology or product is commercialized but excludes the increase of production capacity, product development or product marketing.

    Investment is in the form of:

    • cash with no obligation to be repaid; or
    • holding of paid-up capital, i.e. investment which is paid in cash in respect of ordinary shares.

    Cessation of Tax Deduction

    The deduction allowed to a qualifying person under these Rules shall cease in the basis period for a year of assessment when the BioNexus status company begins the commercialization of the activities in respect of which the investment is made, which is based on the date of the first sales invoice.

    Disposal of Investment in the form of holding of Paid-up Capital in respect of Ordinary Shares

    Where an investment is in the form of holding paid-up capital, the ordinary shares shall not be disposed of within five years from the date of the last investment

    In the event that the ordinary shares are sold for a sale consideration within five years of the date of the investor’s latest investment, then the amount received by the investor shall be taxable to the investor upon receipt of the proceeds.

    • The taxable amount shall not exceed the total tax deduction claimed in relation to the investment.

    Non-application

    1. has made an investment in BioNexus status company which has been granted an exemption under the Income Tax (Exemption)(No. 18) Order 2007;
    2. has made a claim for reinvestment allowance under Schedule 7A to the Income Tax Act 1967(“ITA1967”) or investment allowance for the service sector under Schedule7B to the ITA1967;
    3. has been granted an incentive under the Promotion ofInvestmentsAct1986;
    4. has been granted an exemption under section 127 of the ITA1967;
    5. has made a claim for deduction under any rules made under section 154 of the ITA1967 except –
      1. the rules in relation to an allowance under Schedule3 to the ITA1967 (i.e. rules in relation to capital allowance, etc.);
      2. the Income Tax (Deduction for Audit Expenditure) Rules 2006;
      3. the Income Tax (Deduction for Cost relating to Training for Employees for the Implementation of Goods and Services Tax) Rules 2014; or
      4. the Income Tax (Deduction for Expenses in relation to Secretarial Fee and Tax Filing Fee) Rules 2014.
    20